Characteristically, overexpression of IL-8 has been associated with tumour progression and metastasis 21, and in a clinical trial of metronomic oral VRL, patients who benefited from this therapy tended to have low levels of IL-8 10. This evidence concerns the gene CXCL8 and neoplasm.